![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1288782
¼¼°èÀÇ Áý´Ü°ËÁø ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)Global Population Screening Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030 |
Áý´Ü°ËÁø ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³âÀÇ Á¶»ç ±â°£ Áß ¿¬Æò±Õ 7.48%ÀÇ CAGR·Î 2022³â 353¾ï ´Þ·¯¿¡¼ 2030³â ¾à 675¾ï 7,000¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
Áý´Ü°ËÁøÀº ƯÁ¤ Áúº´À̳ª °Ç° »óÅÂÀÇ Á¸À縦 È®ÀÎÇϱâ À§ÇØ ¸¹Àº ¼öÀÇ °³ÀÎ(ÀϹÝÀûÀ¸·Î ƯÁ¤ Áý´Ü)À» ü°èÀûÀ¸·Î °Ë»çÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. Áý´Ü°ËÁøÀÇ ¸ñÀûÀº Ä¡·á°¡ ´õ È¿°úÀûÀÌ°í ´õ ³ªÀº °Ç° °á°ú¸¦ °¡Á®¿Ã ¼öÀÖ´Â Ãʱ⠴ܰ迡¼ Áúº´À̳ª »óŸ¦ ¹ß°ßÇÏ´Â °ÍÀÔ´Ï´Ù. Áý´Ü°ËÁø¿¡´Â Ç÷¾× °Ë»ç, ¿µ»ó °Ë»ç, ½Åü °Ë»ç µî ´Ù¾çÇÑ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. Áý´Ü°ËÁø ÇÁ·Î±×·¥ÀÇ ¿¹·Î´Â À¯¹æÃÔ¿µ¼ú °ËÁø(À¯¹æ¾Ï), ÀڱðæºÎ¾Ï °ËÁø(ÀڱðæºÎ¾Ï), ´ëÀå³»½Ã°æ °ËÁø(´ëÀå¾Ï) µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áý´Ü°ËÁøÀº ½ÉÀ庴¿¡ ´ëÇÑ ÄÝ·¹½ºÅ×·Ñ ¹× Ç÷¾Ð °Ë»ç¿Í °°Àº ƯÁ¤ ÁúȯÀÇ À§Çè ¿äÀÎÀ» ÆÄ¾ÇÇÏ´Â µ¥¿¡µµ »ç¿ëµË´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ÀϹÝÀûÀ¸·Î ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ³ª °øÁß º¸°Ç ±â°ü¿¡ ÀÇÇØ Á¶Á÷µÇ°í ½ÃÇàµÇ¸ç, Á¾Á¾ Á¤ºÎ ÀÚ±ÝÀ¸·Î Áö¿øµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥ÀÇ ¼³°è¿Í ½ÇÇàÀº ´ë»ó Áúº´À̳ª »óÅÂ, °ËÁø ´ë»ó Áý´ÜÀÇ Æ¯¼º, »ç¿ë °¡´ÉÇÑ °ËÁø ¹æ¹ý ¹× ±â¼ú¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. Áý´Ü°ËÁøÀº Áúº´À̳ª »óŸ¦ Á¶±â¿¡ ¹ß°ßÇÏ´Â È¿°úÀûÀÎ ¹æ¹ýÀÌÁö¸¸, ´ÜÁ¡µµ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ÀϺΠ¼±º° °Ë»ç´Â À§¾ç¼º ¶Ç´Â À§À½¼º °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ºÒÇÊ¿äÇÑ °ÆÁ¤°ú Áø´ÜÀ» °£°úÇÏ´Â °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠ°³ÀÎÀº Á¢±Ù¼ºÀÌ ¶³¾îÁö°Å³ª ÇÁ¶óÀ̹ö½Ã ¹× ÈÄ¼Ó Á¶Ä¡ ºñ¿ë¿¡ ´ëÇÑ ¿ì·Á µî ¿©·¯ °¡Áö ÀÌÀ¯·Î ¼±º° °Ë»ç ÇÁ·Î±×·¥¿¡ Âü¿©ÇÏÁö ¾Ê±â·Î °áÁ¤ÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº Ä¡·á È¿°ú°¡ ³ôÀº ¸¸¼ºÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±â¼ú ¹× °ËÁø ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ´õ¿í Á¤È®Çϰí È¿À²ÀûÀÌ¸ç ºñ¿ë È¿À²ÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î »õ·Î¿î ¿µ»ó ±â¼ú°ú ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¸¦ ÅëÇØ Áúº´À» ´õ ºü¸£°í Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼¼°è ¸¹Àº Á¤ºÎµéÀº Àα¸ °ËÁø ÇÁ·Î±×·¥ÀÇ Á߿伺À» ÀνÄÇϰí ÀÌ·¯ÇÑ ÇÁ·Î±×·¥À» È®´ëÇϱâ À§ÇØ Àڱݰú Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ´Â Àα¸ °ËÁø ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. Àα¸ °ËÁøÀÇ ÀÌÁ¡ÀÌ »ç¶÷µé¿¡°Ô ÀÎ½ÄµÇ°í °ËÁø ÇÁ·Î±×·¥ÀÇ Á¤È®¼º°ú È¿°ú°¡ Çâ»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ÇÁ·Î±×·¥ÀÇ ¼ö¿ë°ú ¼ö¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ç¶÷µéÀº °Ç°À» À¯ÁöÇϰí Áúº´ ¹ßº´À» ¿¹¹æÇϱâ À§ÇØ ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Áý´Ü°ËÁø ÇÁ·Î±×·¥Àº ¿¹¹æ ÀÇ·áÀÇ Áß¿äÇÑ ºÎºÐÀ̱⠶§¹®¿¡ ÀÌ·¯ÇÑ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾÷°è ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·Âµµ¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°è Áý´Ü°ËÁø ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áý´Ü°ËÁø »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº º» ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áý´Ü°ËÁø ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ÀÌ Á¶»ç º¸°í¼´Â ½ÃÀå ÁÖ¿ä ±â¾÷ÀÇ Á¾ÇÕÀû °³¿ä¿Í ¼¼°è °æÀï ȯ°æ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °üÁ¡À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ¼½¼ÇÀº ÁÖ¿ä M&A, ¹Ì·¡ ¿ª·®, ÆÄÆ®³Ê½Ê, À繫 °³¿ä, Çù¾÷, ½ÅÁ¦Ç° °³¹ß, ½ÅÁ¦Ç° Ãâ½Ã µî ´Ù¾çÇÑ Àü·«Àû ¹ßÀüÀ» Æ÷ÇÔÇÑ °æÀï ±¸µµÀÇ ÀüüÀûÀÎ °üÁ¡À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù..
ÁÖ : ±â¾÷ °³¿ä¿¡¼ À繫ÀÇ »ó¼¼ ³»¿ª°ú Ãֽа³¹ßÀº ÀÔ¼ö »óȲ¿¡ µû¶ó Á¦°ø °¡´ÉÇϳª ºñ°ø°³ ȸ»çÀÇ °æ¿ì, ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.
KSA 23.07.05The global demand for Population Screening Market is presumed to reach the market size of nearly USD 67.57 BN by 2030 from USD 35.3 BN in 2022 with a CAGR of 7.48% under the study period 2023-2030.
Population screening refers to the systematic testing of a large group of individuals, typically a specific population, to identify the presence of a particular disease or health condition. The goal of population screening is to detect the disease or condition at an early stage when treatment is more effective and can lead to better health outcomes. Population screening can involve a variety of tests, including blood tests, imaging tests, and physical exams. Examples of population screening programs include mammography screening (breast cancer, Pap smear screening (cervical cancer), and colonoscopy screening(colon cancer). Population screening can also be used to identify risk factors for certain diseases, such as cholesterol and blood pressure screening for heart disease. Population screening programs are typically organized and implemented by healthcare providers or public health agencies, often with support from government funding. The design and implementation of population screening programs can vary depending on the disease or condition being targeted, the characteristics of the population being screened, and the available screening methods and technology. While population screening can be an effective way to identify diseases and conditions at an early stage, it can also have drawbacks. For example, some screening tests can produce false-positive or false-negative results, leading to unnecessary worry or missed diagnoses. Additionally, some individuals may choose not to participate in screening programs for various reasons, including lack of access or concerns about privacy or the cost of follow-up care.
Population screening programs can help to detect chronic diseases at an early stage, when treatment is more effective, and thus play an important role in reducing the burden of these diseases. Advances in technology and screening methods are making population screening programs more accurate, efficient, and cost-effective. For example, new imaging technologies and biomarker tests are enabling earlier and more accurate detection of diseases. Many governments around the world are recognizing the importance of population screening programs and are providing funding and support to expand these programs. This is driving the growth of the population screening market. As people become aware of the benefits of population screening and the accuracy and efficacy of screening programs improve, the acceptance and uptake of these programs are increasing. There is a growing trend towards preventive healthcare, as people seek to maintain their health and prevent the onset of diseases. Population screening programs are an important part of preventive healthcare, and the demand for these programs is therefore increasing.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of population screening. The growth and trends of population screening industry provide a holistic approach to this study.
This section of the population screening market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Population Screening market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the population screening market include Agilent Technologies Inc., Thermo Fisher Scientific, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Quest Diagnostics, Illumina Inc., ARUP Laboratories, Novogene Co. Ltd., LGC Limited, Gene by Gene Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies